Aurobindo receives approval from Medicines Control Council (MCC) to market nine  products in South Africa. The products are said to have a generic market size of 165 million South African brands in the local market

Pharmaceutical firm Aurobindo Pharma Ltd has received approval from the MCC to manufacture and market nine products in South Africa. These products have a generic market size of 165 million South African brands in the local market. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.

Aurobindo now has 31 marketing authorizations approved by the MCC, the company added. Out of the nine products — Zinoxime and Yomax — are anti-infective while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular drugs.
The other products that received the approval include — Auro-Finasteride, Zolid, Lazivir and Profina.

The products approved are as follows:

 Product Name Active Ingredient  Dosage Form  Strength  Category
 1  Auro-Lisinopril Co  Lisinopril+HCTZ  FDC  10+12.5mg, 20+12.5mg  CVS
 2  Auro-Amlodipine  Amlodipine  Tablet  5mg, 10mg  CVS
 3  Auro-Finasteride  Finasteride  Tablet  5mg  BPH
 4  Zinoxime  Cefuroxime Axetil  Tablet  125mg, 250mg, 500mg  Anti-infective
 5  Zolid  Sertraline HCL  Tablet  50mg, 100mg  CNS
 6  Yomax  Amoxycillin  Capsules  250mg, 500mg  Anti-infective
 7  Lazivir  Lamivudine/Zidovudine+Abacavir  FDC  150/300+300 mg  ARV
 8  Lisinozide  Lisinopril+HCTZ  Tablet  10mg, 20mg  CVS
 9  Profina  Finasteride  Tablet  5mg  BPH
(FDC Fixed Dose Combination, CVS: Cardio Vascular System, BPH: Benign Prostatic Hyperplasia, CNS: Central Nervous System, ARV: Anti-RetroVirals)